Release Date: 16 January 2025
Antibody-drug conjugates (ADCs) are being explored as a promising therapeutic approach for prostate cancer, a disease where novel treatment options are urgently needed, particularly for advanced and metastatic cases. Desp...
Release Date: 15 January 2025
Antibody-drug conjugates (ADCs) represent a promising yet largely untapped commercial opportunity in leukemia treatment. The only ADC currently approved for leukemia is Besponsa (inotuzumab ozogamicin), developed by Pfize...
Release Date: 15 January 2025
Antibody drug conjugates (ADCs) hold potential as a future treatment option for pancreatic cancer, a notoriously aggressive and difficult-to-treat malignancy. Currently, no ADCs have been approved for pancreatic cancer, b...
Release Date: 09 January 2025
Columvi (glofitamab-gxbm), approved in June 2023, is one of the latest entries in the rapidly expanding bispecific antibody market, showing impressive early success. Developed by Genentech and marketed by Roche, Columvi i...
Release Date: 09 January 2025
Tecvayli (teclistamab-cqyv), approved by the FDA in 2022, is a groundbreaking bispecific antibody designed for the treatment of relapsed or refractory multiple myeloma. Multiple myeloma, a cancer of the plasma cells, is n...
Release Date: 09 January 2025
Blincyto (blinatumomab), approved by the FDA in 2014, holds the distinction of being the first bispecific antibody to receive approval, marking a pivotal moment in the development of targeted immunotherapies. Designed as ...
Release Date: 09 January 2025
A significant advancement in cancer research has unveiled new avenues in combating aggressive forms of cancer, particularly pancreatic cancer. Scientists have discovered a peptide inhibitor known as D’20, which spec...
Release Date: 09 January 2025
The evolution of targeted cancer therapies has led to the emergence of bispecific antibody-drug conjugates (BsADCs), representing a sophisticated approach that combines the dual-targeting capabilities of bispecific antibo...
Release Date: 09 January 2025
The bispecific antibodies market has emerged as a transformative segment within the biopharmaceutical industry, demonstrating rapid innovation and commercial success. Since the approval of the first bispecific antibody, B...
Release Date: 08 January 2025
Vabysmo (faricimab), approved by the FDA in 2022, is one of the most innovative bispecific antibodies on the market, quickly rising to prominence as one of the top-selling treatments. Designed to target both vascular endo...
Release Date: 08 January 2025
Hemlibra (emicizumab), approved by the FDA in 2017, is one of the most prominent and successful bispecific antibodies in the global pharmaceutical market. Specifically designed to treat hemophilia A, a rare genetic disord...
Release Date: 03 January 2025
KRAS mutations are among the most common oncogenic drivers in cancer, implicated in a wide range of malignancies, including pancreatic, colorectal, and lung cancers. Traditionally viewed as “undruggable,” the ...
Release Date: 18 December 2024
CD40 and its ligand, CD40L, play critical roles in the immune response, particularly in the activation of antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells. This interaction is crucial for ...
Release Date: 18 December 2024
Saudi Arabia's pharmaceutical market stands as one of the largest and most dynamic in the Middle East, driven by a growing population, increasing life expectancy, and rising prevalence of lifestyle-related diseases. The m...
Release Date: 18 December 2024
The United Arab Emirates' pharmaceutical market represents one of the most sophisticated and rapidly evolving healthcare sectors in the Gulf region, characterized by high per capita healthcare spending and strong regulato...